Prospective validation obtained in a similar group of patients and with similar high throughput biological tests failed to confirm signatures for prediction of response to chemotherapy and survival in advanced NSCLC: a prospective study from the European Lung Cancer Working Party

Prospective validation obtained in a similar group of patients and with similar high throughput biological tests failed to confirm signatures for prediction of response to chemotherapy and survival in advanced NSCLC: a prospective study from the European Lung Cancer Working Party

Aim: Cisplatin doublets are standard 1st line treatment for advanced non small cell lung cancer (NSCLC), without accurate predictor for response and survival, but important toxicity. Our aims were to identify predictive (for response) and prognostic (for survival) biological signatures in patients w...

Full description

Bibliographic Details
Main Authors: Thierry eBerghmans, Lieveke eAmeye, Jean-Jacques eLafitte, Benoit eColinet, Alexis eCortot, Ingrid eCsToth, Stéphane eHolbrechts, Jacques eLecomte, Céline eMascaux, Anne-Pascale eMeert, Marianne ePaesmans, Michel eRichez, Arnaud eScherpereel, Christian eTulippe, Luc eWillems, Tiffany eDernies, Nathalie eLeclercq, JEAN PAUL eSCULIER
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-01-01
Series:Frontiers in Oncology
Subjects:
Survival
chemotherapy
miRNA
mRNA
Non-small cell lung cancer
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00386/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00386/full

Similar Items